Buprenorphine, Buprenorphine With Naloxone, Methadone
Treatment of opioid dependence within a framework of medical, social and psychological treatment. Maintenance and detoxification (withdrawal).
Access path
- Mar 2023Recommended · restricted
- PBS listing · Authority Required
From the public summary
6.1 The PBAC considered the interim report for the ODTP PMR addressing the Review TOR and noted the stakeholder input to the PMR, including targeted consultation with people participating in ODT programs.PSD · Mar 2023
6.2 The PBAC accepted the key findings presented in the interim Review Report.PSD · Mar 2023
Cost-effectiveness
This is a post-market review of existing PBS listings addressing affordability and access issues. No economic evaluation or ICER was conducted; the submission is a policy/listing restructuring exercise.
The PBAC noted the PBS financial impact associated with implementing this listing under the Section 100 HSD Program commencing 1 July 2023 is expected to be low and that cost estimates would be finalised by the Department out of session. PBAC · 2023
Decision context
PopulationAdults and patients with opioid dependence requiring treatment through community pharmacy dosing or correctional facilities, receiving buprenorphine (sublingual tablets and modified-release injections), buprenorphine with naloxone (sublingual films), or methadone (oral liquid).
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Mar 2023 | Recommended · restricted | — | — | Other |
Similar precedents
Regulatory · TGA
Label narrower than PBS population — PBAC restricts to medical/social/psychological framework, community pharmacy or correctional settings, and specific formulations; TGA label is broader.